Michael Burry's Zoetis Thesis: 15% Annual Returns via Value Rotation
Summary
Speaker analyzes Zoetis (ZTS) as a value investment, citing Michael Burry's thesis of 15% annual returns over 15 years. The speaker notes a rotation from AI to value stocks, with ZTS benefiting from washed-out growth investors. Financial health remains strong despite slight guidance revisions, supported by high return on invested capital. Valuation is deemed cheap at a 12 P/E, driven by market growth and buybacks. Risks include pharmaceutical regulatory issues and drug expirations, though a robust pipeline mitigates immediate cliffs.
Episode sections
- 0:00 – 1:59
Introduction and Michael Burry's Position
Speaker introduces Zoetis (ZTS) as a veterinary pharma company with a significant stock decline. Notes Michael Burry's 'fat pitch' thesis projecting 15% annual returns for 15 years, potentially yielding an 8x return. Mentions Burry views it as a rotation play from AI to value.
- 1:59 – 2:38
Financial Health and Guidance
Speaker notes slight downward revision in revenue and net income guidance but maintains profitability, margins, and returns are strong. Highlights adjusted EPS of 6 versus reported 5.5, stable capex, and a pipeline of 12 new drugs with key expirations between 2030-2042.
- 2:38 – 3:38
Capital Allocation and Valuation
Discusses Zoetis's focus on buybacks funded by convertible debt, noting a $2B annual cash flow against a $32B market cap. Speaker argues a P/E ratio of 12 is cheap given projected 10.73% veterinary market growth, resulting in a combined 12% return from growth, buybacks, and dividends.
- 3:38 – 5:20
Investment Thesis and Risk Profile
Speaker places ZTS in the value quadrant, estimating a conservative 10% market-like return. Acknowledges higher volatility inherent in pharmaceuticals due to regulatory risks and competition but highlights high return on invested capital and detachment from AI bubble dynamics.
Claims worth verifying
Michael Burry has a 'fat pitch' on Zoetis projecting 15% possible returns for the next 15 years per year.
Unidentified speaker (speaker_0) ·0:33
How to verify: Check Michael Burry's 13F filings via SEC EDGAR for Q3/Q4 2026 to confirm Zoetis (ZTS) position size and classification as a 'fat pitch' if disclosed in notes, or review Burry's public commentary/interviews from 2026-08-15 to 2026-11-15. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceZoetis stock is down significantly.
Unidentified speaker (UNKNOWN) ·0:14
How to verify: Compare Zoetis (ZTS) closing price on 2026-11-15 to its price 6-12 months prior using Yahoo Finance or Bloomberg. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Zoetis revised guidance slightly down for revenue and net income, but remains profitable with great margins.
Unidentified speaker (speaker_0) ·1:59
How to verify: Review Zoetis (ZTS) Q3 2026 earnings release or press update via SEC EDGAR (8-K) or company investor relations page for revised guidance figures. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceAdjusted earnings per share are 6, while reported EPS is 5.5.
Unidentified speaker (speaker_0) ·2:18
How to verify: Check Zoetis (ZTS) Q3 2026 earnings report via SEC EDGAR for Adjusted EPS and GAAP EPS figures. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceZoetis has two drugs expiring between 2030-2042 and 12 new drugs in the pipeline.
Unidentified speaker (speaker_0) ·2:18
How to verify: Review Zoetis (ZTS) latest annual report (10-K) or pipeline update on their investor relations website for patent expiration dates and pipeline drug counts. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceZoetis spent money on a convertible buyback.
Unidentified speaker (speaker_0) ·0:53
How to verify: Check Zoetis (ZTS) SEC filings (8-K or 10-Q) for details on convertible debt issuance and share repurchase programs during the verification period. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceZoetis has a $32 billion market cap.
Unidentified speaker (speaker_0) ·2:58
How to verify: Check Zoetis (ZTS) market capitalization on 2026-11-15 via Yahoo Finance or Bloomberg. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Zoetis generates $2 billion per year in cash flow.
Unidentified speaker (speaker_0) ·2:58
How to verify: Review Zoetis (ZTS) latest quarterly or annual financial statements (10-Q/10-K) via SEC EDGAR for Operating Cash Flow or Free Cash Flow figures. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceThe veterinary medicine market is projected to grow at 10.73%.
Unidentified speaker (speaker_0) ·3:18
How to verify: Identify the specific market research report cited by the speaker (likely from a firm like Grand View Research or similar) and verify the CAGR projection for the global veterinary pharmaceutical market. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Zoetis trades at a P/E ratio of 12.
Unidentified speaker (speaker_0) ·2:58
How to verify: Calculate Zoetis (ZTS) trailing twelve-month (TTM) P/E ratio using the stock price and EPS from Q3 2026 filings via SEC EDGAR. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceDo your own research
- Verify Michael Burry's actual holdings in Zoetis (ZTS) via SEC Form 13F filings for the relevant quarter.
- Check Zoetis's latest quarterly earnings report for the specific revenue and net income guidance revisions mentioned.
- Review Zoetis's S-3 or S-4 filings to confirm the terms and usage of convertible debt used for share buybacks.
- Analyze the FDA approval status and expiration dates of the two drugs mentioned (expiring 2030-2042) and the 12 pipeline drugs.
- Compare Zoetis's current P/E ratio of 12 against historical averages and peer veterinary pharma companies.
- Assess the 10.73% veterinary market growth forecast source and its applicability to Zoetis's specific geographic exposure.
- Evaluate the regulatory risk profile of veterinary pharmaceuticals compared to human pharma.
- Confirm the 'washed out' growth investor claim by analyzing institutional ownership changes over the past 12 months.
Full transcriptexpand
- 0:00
- Unidentified speaker (speaker_0): Good day, fellow investors. Welcome to the Modern Value Investing Podcast with Sven Carlin, where we compound investment returns as well as investment knowledge in order to help you achieve your financial goals.
- 0:14
- Unidentified speaker (UNKNOWN): Good
- 0:14
- Unidentified speaker (speaker_0): day, fellow investors. A lot of questions about Zoetis, the pharma company for animals. And of course, when there are a lot of comments, it means the stock is down and this one is down significantly. On top of that, Michael Burry has it as a fat pitch, which means 15% possible
- 0:33
- Unidentified speaker (speaker_0): returns for the next 15 years per year. That means you double after 5, double after 10, and then double again. That's an 8x. So the risk and reward is very interesting to check this. On the short term, he sees also as a rotation play
- 0:53
- Unidentified speaker (speaker_0): into value as the AI boom turns into bust and the money flows into more valuable companies. They did a convertible buyback at 120, spent a lot of money, but Burry says it's still value. The company says they don't know when US markets will stabilize. 6, 12, 18 months.
- 1:13
- Unidentified speaker (speaker_0): That's something that Wall Street hates, uncertainty. But there is buybacks, dividends. Bury also looks at the volume and the traded amount of stocks. So all those growth gamblers buying a few years ago have now been washed, and now we have different
- 1:33
- Unidentified speaker (speaker_0): investors owning the stock. On top of that, high return on invested capital, quality.
- 1:39
- Unidentified speaker (speaker_0): fat pitch investment. By the way, if you want to learn more about value investing, my new handbook that covers most of the things you need to know to compound for the long term is out. Check it on Amazon in the link in the description below. Let's see if Zoetis can be the piggy bank for your future.
- 1:59
- Unidentified speaker (speaker_0): Guidance has been revised a little bit, just slightly down revenue, net income, still profitable, still great returns, still great margins, everything looks good. Adjusted earnings per share six. Reported okay, 5.5. But if we look at the history, slow and
- 2:18
- Unidentified speaker (speaker_0): steady growth as the market grows, net income growing, everything looks good, capex stable, growing a little. bit, investing into new drugs, two drugs expiring, the most important 2030-2042, 12 new in the pipeline, so interesting. Repurchase focus, they
- 2:38
- Unidentified speaker (speaker_0): borrowed some money to do that with convertibles because they saw it as very valuable. Stock went down a little bit more, but okay. Focus Focuses is on buybacks, returning cash to shareholders. a dividend is there. When we look at the cash flows, with the weakness, 2 billion per year, more for
- 2:58
- Unidentified speaker (speaker_0): buybacks, a little bit less for the dividend, 2 billion on the 32 billion market cap, there is the dividend yield, the buyback growth. Okay, but all of that with a P ratio of 12 looks cheap. Because if we look at the market projections, those are always linear. But the
- 3:18
- Unidentified speaker (speaker_0): growth of just the market for veterinary medicine is projected at 10.73%. It is an oligopoly, free players, interesting to look at. And if we look at not 10% growth, but 7% growth plus buybacks plus the dividend, that's already 12%.
- 3:38
- Unidentified speaker (speaker_0): On top of that, we have to think about the high return on invested capital, unloved by the market. So Burry loves these crashes and then buying these stocks that he has been following for years on the cheap. If we have to put it on our quadrant, let's put it here. So 12% should be a
- 3:58
- Unidentified speaker (speaker_0): little bit more here, but to be more conservative, 10% more. market-like risk. So I am crowding a little bit the value side of the value investment quadrant so we can follow it over time. So to conclude, it sounds very interesting. Pharmaceuticals, you have to always accept a
- 4:18
- Unidentified speaker (speaker_0): little bit more of volatility there. A drug doesn't get approved, a this, a that, something else, a competitor makes this. So you will have to accept this. You can see it here, volatility there. It will continue. But if you want a good business, high return on invested capital, good
- 4:38
- Unidentified speaker (speaker_0): position, profitable, growing, good market, everything good, detached from AI bubbles or things like that. Perhaps with AI they can even improve things a little bit. That is something very very interesting. I understand Barry's position here looks like a buy. We added it to the quadrant,
- 4:58
- Unidentified speaker (speaker_0): and over time we'll learn more, understand more, and who knows, perhaps the market will give us even better opportunities. Thanks for listening. If you have any comments, please let me know. If you enjoyed this podcast, please leave a five 5-star star review, as it means a lot to me.
- 5:15
- Unidentified speaker (speaker_0): Thank you and I'll be speaking to you in the next episode.
More from Modern Value Investing with Sven Carlin
S&P 500 (459 to 440) - 6 Extremely Interesting Investing Stories (PNW, SOLV, GNRC, ECHO, GEN, IVZ)
Episode discussion: Sven Carlin analyzes six stocks including PNW, SOLV, GNRC, SATS, GEN, IVZ and dismisses several others as risky or overvalued.
Speakers’ claims: Sven Carlin reviews six specific equities, arguing that Pinnacle West (PNW) is overvalued despite strong fundamentals, while Solventum (SOLV) suffers from financial engineering risks. He identifies Generac (GNRC) as a viable AI infrastructure play but warns that EchoStar (SATS) carries extreme risk due to its reliance on SpaceX's valuation. Carlin criticizes Gen Digital (GEN) for management debt and acquisition strategy, and views Investco (IVZ) as fairly priced relative to market risk. He briefly dismisses other S&P 500 stocks like Textron, J.M. Smucker, and GoDaddy due to cyclicality, debt, or competition.
When To Buy Mosaic Stock NYSE MOS
Episode discussion: Sven Carlin analyzes Mosaic's phosphate cost crisis, dividend risk, and potential entry point for value investors
Speakers’ claims: Sven Carlin discusses Mosaic's current financial strain caused by soaring input costs for ammonia and sulfur, which have made phosphate production unprofitable. He notes that while the company is burning cash and may need to draw on its credit revolver, the speaker views the resulting low application rates as creating future pent-up demand. Carlin contrasts Mosaic's volatility with peers like Nutrien and highlights the undervaluation of its Estevan mine relative to BHP's Jansen project. He concludes that despite the risks, including a potential dividend cut, he plans to initiate a small position if the stock remains depressed, arguing that a true bargain requires a significantly higher yield than currently offered.